… remodeling of the heart ventricles [59,60]. The expression of Gal-3 in the heart is usually low,
while in heart failure both its … This signaling pathway would have therapeutic potential [152]. …

… the risk for heart failure development. This risk evolves from functional and structural alterations
induced by diabetes in the heart, a cardiac entity termed diabetic cardiomyopathy (DbCM…

… observed in the hearts of heart failure patients, and AMPKα2 overexpression promoted
PINK1 phosphorylation and enhanced mitophagy to prevent heart failure in mice, 68 suggesting …

… of heart failure but cannot save dead heart cells, clinicians began to look for a new way to
treat heart failure after MI. Heart transplantation remains the only cure for heart failure patients, …

… Heart failure is a growing health burden worldwide … of heart failure, no treatment that targets
reactive oxygen species (ROS) directly has entered the clinical arena yet. In the heart, ROS …

… In contrast to the wealth of proven therapies for heart failure with reduced ejection fraction
(HFrEF), therapeutic efforts in the past have failed to improve outcomes in heart failure with …

… disease, such as hypertension, cardiac hypertrophy and heart failure. Hereby, we will discuss
the therapeutic potential of mTOR inhibitors in treating several classes of cardiovascular …

… Assessing and grading congestion in acute heart failure: a scientific statement from the
acute heart failure committee of the heart failure association of the European Society of …

… A major obstacle that hampers development of new therapeutics in heart failure is the
pathophysiologic heterogeneity of the disease. The clinical syndrome of heart failure can be …

… Separate studies demonstrated that circulating ketone concentrations and cardiac ketone
utilization are increased in a variety of clinical conditions, including heart failure with reduced …